Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2020

View Archived Issues

BCHT's live attenuated influenza virus vaccine receives approval in China

Finding the silent majority

First-in-human data for EHP-101

New phase III trials evaluate switch to doravirine/islatravir in HIV patients on other regimens

Increasing immune activity improves autoimmunity

IPA enters AI collaboration to develop therapeutics and vaccines against SARS-CoV-2 coronavirus

Nitto Denko initiates phase II study in Japan with ND-L02-s0201 for IPF

Dynavax, University of Queensland and CEPI collaborate to develop COVID-19 vaccine

Phase I results presented for rongliflozin

Tissue kallikrein as a new serum biomarker to predict DCI following aSAH

Kikkoman, Chiba University patent high-affinity IgE receptor suppressors

Leo Pharma synthesizes new RORgammaT ligands

New IRAK-4 inhibitors identified at Gilead

New antibacterials discovered at Recreo Pharmaceuticals

Merck & Co. discloses new IDO-1 inhibitors

Tau protein plays role in autism spectrum disorder

XIST is a novel therapeutic target for treating laryngeal squamous cell carcinoma

SIGA agrees to provide Tpoxx in support of Turnstone's SKV vaccinia oncolytic immunotherapy program

Cytoo and Asklepios collaborate to select gene therapy candidate for rare muscle disorder

Mutated TTC12 causes primary ciliary dyskinesia, revealing diverse dynein assembly in cilia/flagella

Phase III BOSTON study of Xpovio in multiple myeloma meets primary endpoint

Sarclisa receives FDA approval for relapsed refractory multiple myeloma

Unum prioritizes resources on advancement of BOXR-1030

Tilt opens first-in-human study of oncolytic adenovirus TILT-123 for metastatic melanoma

Omeros reports new data from pivotal trial of narsoplimab for HSCT-TMA